Recent progress in the diagnosis and treatment of patients with defects in early B-cell development

Current Opinion in Pediatrics

Volumn 11, Issue 6, 1999, Pages 528-532

  Minegishi, Yoshiyuki ^a   Rohrer, Jurg ^a   Conley, Mary Ellen ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

AGAMMAGLOBULINEMIA; ARTICLE; GENE MUTATION; GENE THERAPY; HUMAN; IMMUNOTHERAPY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; X CHROMOSOME LINKAGE;

AGAMMAGLOBULINEMIA; ANIMALS; CHILD; HUMANS; LINKAGE (GENETICS); MUTATION; PHENOTYPE; PROTEIN-TYROSINE KINASES; X CHROMOSOME;

EID: 0032749742     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199912000-00010     Document Type: Article

References (49)

1. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:279-290.
2. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al.: The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226-233.
3. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al.: CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993, 259:990-993.
4. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al.: The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-300.
5. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G: CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:541-543.
6. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al.: Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
7. Derry JMJ, Ochs HD, Francke U: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 78:635-644.
8. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al.: A single ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science 1995, 268:1749-1753.
9. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al.: Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129-135. Along with Sayos et al. [10•] and Nichols et al. [11•], these investigators showed that the mutations in SH2D1A/SAP/DSHP are responsible for X-linked lymphoproliferative disease.
10. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al.: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462-469. Along with Coffey et al. [9•] and Nichols et al. [11•], these investigators showed that the mutations in SH2D1A/SAP/DSHP are responsible for X-linked lymphoproliferative disease.
11. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, et al.: Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998, 95:13765-13770. Along with Coffey et al. [9•] and Sayos et al. [10•], these investigators showed that the mutations in SH2D1A/SAP/DSHP are responsible for X-linked lymphoproliferative disease.
12. Conley ME, Rohrer J, Minegishi Y: X-linked agammaglobulinemia. Clin Rev Allergy Immunol 1999, 17:in press. This updated review summarizes the molecular genetics and clinical aspects of XLA.
13. Sideras P, Smith CI: Molecular and cellular aspects of X-linked agammaglobulinemia. Adv Immunol 1995, 59:135-223.
14. Conley ME, Cooper MD: Genetic basis of abnormal B cell development. Curr Opin Immunol 1998, 10:399-406.
15. Rawlings DJ: Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function. Clin Immunol 1999, 91:243-253. This is an excellent review of the biochemical function of Btk.
16. Rohrer J, Parolini O, Belmont JW, Conley ME: The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia. Immunogenetics 1994, 40:319-324.
17. Ohta Y, Haire RN, Litman RT, Fu SM, Nelson RP, Kratz J, et al.: Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci USA 1994, 91:9062-9066.
18. Sideras P, Muller S, Shiels H, Jin H, Khan WN, Nilsson L, et al.: Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol 1994, 153:5607-5617.
19. Conley ME, Fitch HM, Cleveland JL, Parolini O, Rohrer J: Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet 1994, 3:1751-1756.
20. Conley ME, Mathias D, Treadway J, Minegishi Y, Rohrer J: Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet 1998, 62:1034-1043. This single-center study examined 101 families in whom the affected boy was presumed to have XLA. The frequency of new mutations and the source of mutations are defined. These data provide a useful resource for genetic counseling.
21. Rohrer J, Conley ME: Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase. Blood 1998, 91:214-221.
22. Vihinen M, Brandau O, Branden U, Kwan SP, Lappalainen I, Lester T, et al.: BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res 1998, 26:242-247.
23. Rohrer J, Minegishi Y, Richter D, Eguiguren J, Conley ME: Unusual mutations in Btk: an insertion, a duplication, an inversion and four large deletions. Clin Immunol 1999, 90:28-37.
24. Kornfeld SJ, Haire RN, Strong SJ, Tang H, Sung SS, Fu SM, et al.: A novel mutation (Cys→Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol Med 1996, 2:619-623.
25. Bykowsky MJ, Haire RN, Ohta Y, Tang H, Sung SS, Veksler ES, et al.: Discordant phenotype in siblings with X-linked agammaglobulinemia. Am J Hum Genet 1996, 58:477-483.
26. Saffran DC, Parolini O, Fitch HM, Rawlings DJ, Afar DE, Witte ON, et al.: A point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 1994, 330:1488-1491.
27. Gasper HB, Lester T, Levinsky RJ, Kinnon C: Bruton's tyrosine kinase in B lymphoid cell lines from X-linked agammaglobulinemia (XLA): the use of protein analysis as a diagnostic indicator of XLA. Clin Exp Immunol 1998, 111:334-338.
28. Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, et al.: Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 1998, 91:595-602. The authors used a highly specific monoclonal antibody and fluorescence-activated cell sorter analysis to demonstrate that the majority of the mutations in Btk result in the absence of Btk protein, probably caused by the impairment of stability of the protein.
29. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al.: Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993, 261:358-361.
30. Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE: Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993, 261:355-358.
31. Khan W, Alt FW, Gerstin RM, Malynn BA, Larsson I, Rathbun G, et al.: Defective B cell development and function in Btk-deficient mice. Immunity 1995, 3:283-299.
32. Kerner JD, Appleby MW, Mohr RN, Chien S, Rawlings DJ, Maliszewski CR, et al.: Impaired expansion of mouse B cell progenitor lacking Btk. Immunity 1995, 3:301-312.
33. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, et al.: Early lymphocyte expression is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994, 180:1955-1960.
34. Puel A, Ziegler SF, Buckley RH, Leonard WJ: Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998, 20:394-397. The authors identified mutations in interleukin-7 receptor in two patients with T(-)B(+)NK(+) severe combined immunodeficiency. This demonstrates that interleukin-7 signaling in not essential for human B-cell development.
35. Conley ME, Sweinberg SK: Females with a disorder phenotypically identical to X-linked agammaglobulinemia. J Clin Immunol 1992, 12:139-143.
36. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, et al.: Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996, 335:1486-1493.
37. Rajewsky K: Clonal selection and learning in the antibody system. Nature 1996, 381:751-758.
38. Minegishi Y, Coustan-Smith E, Wang Y-H, Cooper MD, Campana D, Conley ME: Mutations in the human λ5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998, 187:71-77. This study described a boy with a condition phenotypically identical to XLA who had defects in the gene for λ5/14.1. This is the second example of an autosomal recessive form of agammaglobulinemia.
39. Kitamura D, Kudo A, Schaal S, Muller W, Melchers F, Rajewsky K: A critical role of λ5 protein in B cell development. Cell 1992, 69:823-831.
40. Quartier P, Debra M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al.: Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999, 134:589-596.
41. Lonberg N, Tayler LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al.: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994, 368:856-859.
42. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997, 15:146-156.
43. Bunting KD, Sangster MY, Ihle JN, Sorrentino BP: Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998, 4:58-64. The authors demonstrated that retroviral-mediated JAK3 gene transfer can reconstitute normal immune system in JAK3-deficient mice, which is one of the convincing successes of gene therapy models for congenital genetic disorders.
44. Bunting KD, Flynn KJ, Riberdy JM, Doherty PC, Sorrentino BP: Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci U S A 1999, 96:232-237.
45. Brown MP, Topham DJ, Sangster MY, Zhao J, Flynn KJ, Surman SL, et al.: Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998, 4:1253-1260. This study showed that constitutive expression of CD40 ligand induced by a retroviral vector can improve immune function in CD40 ligand-deficient mice. However, more than 60% of treated mice developed T-cell lymphoproliferative disorders, suggesting current retroviral gene therapy is not adequate for genes that require tight regulation of expression.
46. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON: Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A 1997, 94:13152-13157.
47. Maas A, Dingjan GM, Savelkoul HF, Kinnon C, Grosveld F, Hendriks RW: The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome transgene. Eur J Immunol 1997, 27:2180-2187.
48. Drabek D, Raguz S, De Wit TP, Dingjan GM, Savelkoul HF, Grosveld F, et al.: Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton's tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region. Proc Natl Acad Sci U S A 1997, 94:610-615.
49. Rohrer J, Conley ME: Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood 1999, in press. This paper shows that limited numbers of normal cells are sufficient for the correction of humoral immunity in Btk-deficient mice using competitive bone marrow transplantation.